<DOC>
	<DOCNO>NCT00066404</DOCNO>
	<brief_summary>RATIONALE : Using BG00001 insert gene interferon-beta person 's pleural cavity may improve body 's ability fight cancer . PURPOSE : Phase I trial study effectiveness intrapleural BG00001 treat patient malignant pleural mesothelioma malignant pleural effusion .</brief_summary>
	<brief_title>Intrapleural BG00001 Treating Patients With Malignant Pleural Mesothelioma Malignant Pleural Effusions</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety toxicity intrapleural BG00001 patient malignant pleural mesothelioma malignant pleural effusion . - Determine maximum tolerate dose drug patient . - Determine success gene transfer/interferon beta gene expression patient treat drug . - Determine systemic intrapleural cytokine response cellular humoral immune response patient treated drug . - Determine , preliminarily , tumor response patient treated drug . OUTLINE : This dose-escalation study . Patients receive BG00001 via intrapleural catheter day 1 . Cohorts 3-6 patient receive escalate dos BG00001 maximum tolerate dose ( MTD ) determine . The MTD define dose 1 6 patient experience dose-limiting toxicity . Patients follow weekly 1 month , biweekly 1 month , monthly 4 month , every 6 month 15 year . PROJECTED ACCRUAL : A total 3-18 patient accrue study .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow histologically cytologically confirm diagnosis : Malignant pleural mesothelioma Metastatic malignancy pleural space Originating 1 follow site : Lung Breast Gastrointestinal organ Genitourinary organ Malignant melanoma Failed prior standard therapy comprise chemotherapy , radiotherapy , and/or hormonal therapy Measurable evaluable disease Pleural space involve tumor accessible pleural catheter insertion No malignant pleural effusion secondary lymphoma sarcoma No rapidly reaccumulating , symptomatic pleural effusion thoracentesis pleural catheter insertion require immediate mechanical chemical pleurodesis No known brain metastases Previously treat brain metastasis evidence active growth allow Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Male female Menopausal status Not specify Performance status ECOG 01 Life expectancy Not specify Hematopoietic Granulocyte count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hematocrit least 30 % ( transfusion allow ) Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) ALT AST great 1.5 time ULN Alkaline phosphatase great 1.5 time ULN PT PTT great 1.5 time normal No endstage liver disease No chronic active hepatitis B ( hepatitis B surface antigen negative ) Renal Creatinine great 2.0 mg/dL No endstage renal disease Cardiovascular No unstable angina Pulmonary FEV_1 great 50 % predict ( postpleural drainage ) No severe oxygendependent chronic obstructive pulmonary disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No document immunodeficiency No malignancy within past 5 year except nonmelanoma skin cancer successfully treat localized malignancy bladder prostate gland evidence active disease No lifethreatening illness No known hypersensitivity component study treatment PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior biologic therapy No prior bone marrow transplantation , include stem cell No immunological drug least 2 month study therapy Chemotherapy See Disease Characteristics No chemotherapy least 2 month study therapy Endocrine therapy See Disease Characteristics Concurrent hormonal therapy allow maintain dose receive prior study entry No concurrent steroid Radiotherapy See Disease Characteristics More 4 week since prior radiotherapy No radiotherapy least 2 month study therapy Surgery At least 2 week since prior surgery Other More 4 week since prior cytotoxic agent No concurrent immunosuppressives medication directly indirectly suppress immune system No concurrent experimental therapy pleural cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent penile cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>recurrent anal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>recurrent thymoma thymic carcinoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>recurrent vulvar cancer</keyword>
	<keyword>recurrent vaginal cancer</keyword>
	<keyword>recurrent gestational trophoblastic tumor</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>malignant pleural effusion</keyword>
</DOC>